SUBSCRIBE
SUBSCRIBE

Arcellx Inc.

NEWS
BioCapital
Arcellx Raises $115 Million Series C to Advance Next-Generation CAR-T Therapies
Arcellx, based in Gaithersburg, Maryland, closed on a Series C financing round worth $115 million.
April 13, 2021
 · 
3 min read
 · 
Mark Terry
BioCapital
Pushing to Improve Immunotherapies, Arcellx Raises $85 Million in Series B
The company plans to use the funds raised to advance the ARC-T and sparX programs, including development of a bivalent BCMA-targeted therapy in multiple myeloma and a CD123-targeted treatment in acute myeloid leukemia.
October 3, 2019
 · 
2 min read
 · 
Mark Terry
Load More
JOBS
IN THE PRESS
Biotech Bay
Kite and Arcellx Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program
May 9, 2024
 · 
9 min read
Business
Arcellx Provides First Quarter 2024 Financial Results
May 9, 2024
 · 
5 min read
Biotech Bay
Arcellx to Participate in Two Upcoming May 2024 Investor Conferences
May 7, 2024
 · 
2 min read
Biotech Bay
Arcellx to Participate in the 23rd Annual Needham Virtual Healthcare Conference
April 4, 2024
 · 
2 min read
Biotech Bay
Arcellx to Participate at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference
March 20, 2024
 · 
2 min read
Biotech Bay
Arcellx to Participate at the TD Cowen 44th Annual Health Care Conference
February 29, 2024
 · 
2 min read
Business
Arcellx Provides Fourth Quarter and Year-End 2023 Financial Results and Business Highlights
February 28, 2024
 · 
9 min read
Drug Development
Arcellx Announces Continued Robust Long-Term Responses from Its CART-ddBCMA (anito-cel) Phase 1 Expansion Trial in Patients with Relapsed or Refractory Multiple Myeloma at ASH
December 8, 2023
 · 
10 min read
Business
Kite and Arcellx Announce Expansion in Strategic Partnership
November 15, 2023
 · 
11 min read
Business
Arcellx and Kite Announce Expansion in Strategic Partnership
November 15, 2023
 · 
11 min read
Load More